First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of ds002, an anti-nerve growth factor monoclonal antibody

HIGHLIGHTS

• who: December et al. from the Dalian Medical University, China have published the paper: First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody, in the Journal: (JOURNAL) of 22/02/2021
• what: The aim of this first-in-human study was to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of a single subcutaneous injection of DS002 in healthy volunteers.
• how: The results indicated that Cmax and AUC0-inf increased with dose but did not have a significant dose-linear relationship whilst . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.